Harbor Capital Advisors, Inc. Moon Lake Immunotherapeutics Transaction History
Harbor Capital Advisors, Inc.
- $2.19 Billion
- Q1 2025
A detailed history of Harbor Capital Advisors, Inc. transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Harbor Capital Advisors, Inc. holds 102,020 shares of MLTX stock, worth $4.1 Million. This represents 0.18% of its overall portfolio holdings.
Number of Shares
102,020
Previous 79,648
28.09%
Holding current value
$4.1 Million
Previous $4.31 Million
7.58%
% of portfolio
0.18%
Previous 0.19%
Shares
5 transactions
Others Institutions Holding MLTX
# of Institutions
140Shares Held
58.2MCall Options Held
124KPut Options Held
96.9K-
Bvf Inc San Francisco, CA19.8MShares$794 Million39.28% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$341 Million35.64% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.34MShares$134 Million0.02% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.77MShares$111 Million2.15% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.19MShares$87.9 Million0.02% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $1.48B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...